Vaccine against beta-herpesvirus infection and use thereof

A method for the vaccination of a human or for the treatment of a disease of human comprising administering to the human a human beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient and wherein the beta-herpesvirus us endotheliotropic and/or has a wild type-like virion surface, wherein the beta-herpesvirus is deficient in at least one gene product involved in primary and/or secondary envelopment, wherein the at least one gene product involved in primary involvement is encoded by a gene selected from the group consisting of UL50 and UL53 and homologs of each thereof, wherein the at least one gene product involved in secondary envelopment is encoded by a gene selected from the group consisting of UL94 and UL99 and homologs thereof, and wherein the beta-herpesvirus is human cytomegalovirus.